Galectin Therapeutics Inc.
DE ˙ DB ˙ US3632252025
1,88 € 0,00 (0,00%)
2026-06-04
DEL PRIS
SecurityDE:PHPN / Galectin Therapeutics Inc.
InstitutionLPL Financial LLC
Latest Disclosed Ownership267,200 shares
Latest Disclosed Value $ 745,488
LPL Financial LLC reports 17.85% decrease in ownership of PHPN / Galectin Therapeutics Inc.

On May 6, 2026 - LPL Financial LLC filed a 13F-HR form disclosing ownership of 267,200 shares of Galectin Therapeutics Inc. (DE:PHPN) valued at $598,528 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 325,256 shares of Galectin Therapeutics Inc.. This represents a change in shares of -17.85% during the quarter. The current value of the position is $502,336 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-06 2026-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 267,200 -58,056 -17.85 745 -44.94 0.0002
2026-02-11 2025-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 325,256 -35,012 -9.72 1,353 -11.28 0.0004
2025-11-12 2025-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 360,268 -6,710 -1.83 1,526 97.03 0.0004
2025-08-12 2025-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 366,978 173,500 89.67 774 227.97 0.0003
2025-05-07 2025-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 193,478 54,550 39.26 236 31.84 0.0001
2025-02-11 2024-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 138,928 57,020 69.61 179 -20.44 0.0001
2024-11-08 2024-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 81,908 -5,350 -6.13 225 14.21 0.0001
2024-08-07 2024-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 87,258 32,196 58.47 197 50.38 0.0001
2024-05-10 2024-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 55,062 3,250 6.27 132 52.33 0.0001
2024-02-14 2023-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 51,812 0 0.00 86 -13.13 0.0001
2023-11-13 2023-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 51,812 0 0.00 99 33.78 0.0001
2023-07-31 2023-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 51,812 -500 -0.96 75 -32.11 0.0001
2023-05-10 2023-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 52,312 -10,261 -16.40 110 55.71 0.0001
2023-02-07 2022-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 62,573 500 0.81 71 -30.69 0.0001
2022-11-14 2022-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 62,073 3,539 6.05 101 31.17 0.0001
2022-08-12 2022-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 58,534 0 0.00 77 -18.09 0.0001
2022-05-16 2022-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 58,534 10,900 22.88 94 -5.05 0.0001
2022-02-14 2021-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 47,634 -1,900 -3.84 99 -48.44 0.0001
2021-11-15 2021-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 49,534 -2,500 -4.80 192 14.97 0.0002
2021-08-13 2021-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 52,034 35,750 219.54 167 377.14 0.0002
2021-05-14 2021-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 16,284 -1,300 -7.39 35 -10.26 0.0000
2021-02-12 2020-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 17,584 -1,000 -5.38 39 -22.00 0.0001
2020-11-09 2020-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 18,584 -9,649 -34.18 50 -41.86 0.0001
2020-08-13 2020-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 28,233 1,722 6.50 86 65.38 0.0001
2020-05-14 2020-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 26,511 0 0.00 52 -31.58 0.0001
2020-02-14 2019-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 26,511 0 0.00 76 -21.65 0.0001
2019-11-13 2019-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 26,511 -3,200 -10.77 97 -21.14 0.0002
2019-08-09 2019-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 29,711 -2,166 -6.79 123 -24.54 0.0003
2019-05-08 2019-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 31,877 3,000 10.39 163 64.65 0.0004
2019-02-07 2018-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 28,877 -916 -3.07 99 -44.69 0.0003
2018-11-14 2018-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 29,793 -1,000 -3.25 179 -8.67 0.0004
2018-08-14 2018-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 30,793 7,200 30.52 196 75.00 0.0005
2018-05-15 2018-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 23,593 23,593 112 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.